Cara Therapeutics, Inc. (NASDAQ:CARA) a clinical-stage biopharmaceutical company, is reporting third quarter earnings results on Monday 9th November 2020, after market close.
The consensus estimates from Thomson Reuters are loss of $ 0.6 per share.
For the full year, analysts predict revenues of $ 22.36 million, while looking forward to loss of $ 2.35 per share.
Previous Quarter Performance
Cara Therapeutics, Inc. unfold loss for the second quarter of $ 0.54 per share, from the revenue of $ 5.63 million. The quarterly revenues elevated 8.06 percent compared with the same quarter last year. Wall street analysts are predicting, CARA to report 2Q20 loss of $ 0.67 per share from revenue of $ 5.06 million. The bottom line results beat street analysts by $ 0.13 or 19.40 percent, at the same time, top line results outshined analysts by $ 0.57 million or 11.26 percent.
Stock Performance
On Friday, shares of Cara Therapeutics, Inc. has traded high as $ 14.09 and has cracked $ 13.60 on the downward trend, reaching $ 13.95 with volume of 309.10 thousand shares.
According to the previous trading day, closing price of $ 13.95, representing a 56.42 % increase from the 52 week low of $ 8.88 and a 47.92 % decrease over the 52 week high of $ 26.67.
The company has a market capital of $ 654.07 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Cara Therapeutics, Inc. will be hosting a conference call at 4:30 PM eastern time on 9th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.caratherapeutics.com
Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the bodys peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with chronic kidney disease (CKD) associated pruritus undergoing hemodialysis, as well as in Phase II/III clinical trial for the treatment of dialysis patients suffering from chronic kidney disease-associated pruritus.
